Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion
- 15 January 2012
- journal article
- clinical trial
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (2), 402-407
- https://doi.org/10.1158/0008-5472.can-11-2464
Abstract
The abnormal vasculature of the tumor microenvironment supports progression and resistance to treatment. Judicious application of antiangiogenic therapy may normalize the structure and function of the tumor vasculature, promoting improved blood perfusion. However, direct clinical evidence is lacking for improvements in blood perfusion after antiangiogenic therapy. In this study, we used MRI to assess tumor blood perfusion in 30 recurrent glioblastoma patients who were undergoing treatment with cediranib, a pan-VEGF receptor tyrosine kinase inhibitor. Tumor blood perfusion increased durably for more than 1 month in 7 of 30 patients, in whom it was associated with longer survival. Together, our findings offer direct clinical evidence in support of the hypothesis that vascular normalization can increase tumor perfusion and help improve patient survival. Cancer Res; 72(2); 402–7. ©2011 AACR.Keywords
Other Versions
This publication has 20 references indexed in Scilit:
- Serial Magnetic Resonance Spectroscopy Reveals a Direct Metabolic Effect of Cediranib in GlioblastomaCancer Research, 2011
- HRG Inhibits Tumor Growth and Metastasis by Inducing Macrophage Polarization and Vessel Normalization through Downregulation of PlGFCancer Cell, 2011
- Polarization of Tumor-Associated Macrophages: A Novel Strategy for Vascular Normalization and Antitumor ImmunityCancer Cell, 2011
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent GlioblastomaJournal of Clinical Oncology, 2010
- A Fully Automated Method for Quantitative Cerebral Hemodynamic Analysis Using DSC–MRIJournal of Cerebral Blood Flow & Metabolism, 2010
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- Cancer cells compress intratumour vesselsNature, 2004
- Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerNature Medicine, 2004
- Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapyNature Medicine, 2001
- Effect of Transvascular Fluid Exchange on Pressure–Flow Relationship in Tumors: A Proposed Mechanism for Tumor Blood Flow HeterogeneityMicrovascular Research, 1996